TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms
Jul 21, 2016
The French Institute of Health and Medical Research, Gustave-Roussy Institute, Public Assistance Hospital of Paris, the Henri Becquerel Center, Paris Descartes University, Pierre and Marie Curie University, and University of Paris-Sud have been awarded US Patent No. 9,389,233, "TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms."
In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.
This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).